Phase 1, Multicenter, Open-label, Dose-escalation Study of Sotatercept (ACE-011) in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Sotatercept (Primary) ; Dexamethasone; Lenalidomide; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Biomarker
- 18 Nov 2016 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 18 Nov 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2017.
- 08 Dec 2015 Interim results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.